Fetal Growth Disorders Detection During First Trimester Gestation Through Comprehensive Maternal Circulating DNA Profiling
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
BACKGROUND
Early diagnosis, close follow-up and timely delivery constitute the main elements for appropriate detection and management of Fetal Growth Disorders (FGD). We hypothesized that fetoplacental FGD-associated alterations can be detected in circulating DNA (cirDNA) samples isolated from maternal blood, as early as the first gestational trimester. To study whether markers in maternal cirDNA may facilitate FGD early detection, we profiled plasma cirDNA from maternal samples prospectively collected during first gestational trimester.
METHODS
Plasma cirDNA was isolated from samples prospectively collected during first trimester gestation (n=56). Small, Large and Appropriate for Gestational Age (SGA n=11, LGA n=18, and AGA n=29, respectively) status was determined at birth according to weight and gestational age. cirDNA amount, fragmentation, mitochondrial/nuclear ratio and cirDNA methylation profiles were quantified using qPCR-based assays. Machine learning approaches were applied to build a molecular signature for prediction of LGA and SGA. Prediction accuracy was assessed by Receiving-Operating Curve (ROC) analysis, and Positive and Negative Predictive values (PPV and NPV, respectively) were calculated.
RESULTS
Total concentration of plasma cirDNA, cirDNA fragmentation and ratio of mitochondrial/nuclear cirDNA were increased in SGA and LGA compared to AGA pregnancies. DNA methylation profiles also shown distinctive patterns. Out of the 10 selected loci, we detected 5 genes ( HSD2 , RASSF1 , CYP19A1 , IL10 , and LEP ) showing significant differential methylation differences (p<0.05) across the SGA, AGA and LGA samples at first trimester. We combined these molecular and epigenetic cirDNA markers in a signature that reliably discriminates between FGD and AGA pregnancies with high accuracy (AUC>0.95), achieving 88.8% PPV and 85.7% NPV.
CONCLUSIONS
Our findings show that maternal blood cirDNA profiles accurately detects early gestation FGD. The proposed novel marker panel hold great potential for implementation of low invasive approaches for reliable prediction of FGDs, enabling a disruptive path toward precision medicine in FGD.
